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ABSTRACT
Osteoporosis is prevalent in end‐stage liver disease, but data on long‐term changes in bone mineral density (BMD) and related
fracture incidence after orthotopic liver transplantation (OLT) are scarce. We evaluated BMD changes up to 5 years in consecutive
recipients of a successful OLT at the Leiden University Medical Centre between 2000 and 2011, in whom sequential BMD data were
available. Spinal radiographs were available at time of screening and at 6 and 12 months post‐OLT and were assessed for vertebral
fractures by two independent observers using Genant’s semiquantitative method. Patients were excluded from the study when
started on bisphosphonates. A total of 201 patients (71%men), median age 53 years (range, 18–70 years) were included in the study.
Most common liver pathology was viral (27%) or alcoholic liver disease (25%). All patients received prednisone for at least 6 months
after transplantation and the majority received either tacrolimus or cyclosporine for immunosuppression. At time of screening for
OLT, osteoporosis and osteopenia were found in 18% and 36% of patients at the lumbar spine (LS), respectively, and in 9% and 42% at
the femoral neck (FN), respectively. T‐scores declined significantly at both sites 6 months after OLT, but increased thereafter at the LS,
reaching pretransplantation values at 2 years and remaining stable thereafter. FN T‐scores remained consistently lower than
pretransplantation values. The prevalence of vertebral fractures increased from 56% at screening to 71% at 1 year after OLT, with a
fracture incidence of 34%. BMD changes did not predict fracture risk. Osteoporosis, osteopenia, and vertebral fractures are prevalent
in patients with end‐stage liver disease. An overall decline in BMD is observed within the first 6 months after OLT, with subsequent
recovery to pretransplantation values at the LS, but not at the FN. Vertebral fracture risk is high after OLT regardless of changes in BMD.
© 2014 American Society for Bone and Mineral Research.
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Introduction
Osteoporosis is reported to be prevalent in end‐stage liverdisease, and accelerated bone loss associated with
increased fracture risk has been observed in 25% to 35% of
patients in the first 12 months after orthotopic liver transplanta-
tion (OLT).(1–11) The initial decline in bone mineral density (BMD),
believed to be predominantly due to corticosteroid use for
immunosuppression, is generally followed by a stabilization in
bone mass between 6 and 12 months after OLT, with no further
decrease in BMD thereafter, independently of the use of bone‐
modifying agents such as bisphosphonates.(1,3–6,8,9,12) Data on
natural changes in BMD beyond the first year after OLT are
scarce, however, andmainly based on small studies, or on studies
in patients with exclusive cholestatic liver disease as underlying
liver pathology.(1–9,12–16) Studies were also performed over a
decade ago,(1–5,13–15) before the introduction of currently used
immunosuppressive regimens, which enable the use of signifi-
cantly lower corticosteroid doses post‐OLT, thus precluding
exposure to a high cumulative dose of these agents. Whether the
spontaneous recovery of BMD within the first year after OLT is
also associated with a decreased fracture risk has not been
adequately addressed.
The aims of this studywere to examine changes in BMD after OLT
in a cohort of consecutive liver transplant recipients not receiving
treatment with antiresorptive agents, to identify risk factors for bone
loss after successful OLT and to examine the influence of changes in
BMD on fracture risk within the first year after OLT.
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Consecutive patients who underwent a first OLT at the Leiden
University Medical Centre between January 1, 2000 and
January 1, 2011, and who had sequential BMD measurements
after OLT, were eligible for the study, including 20 patients who
had BMD measurements from 6 months onward after OLT.
Immunosuppressive regimens for OLT consisted of cortico-
steroids for at least 6 months in all patients, with an additional
calcineurin inhibitor: cyclosporine or tacrolimus in the majority,
with mofetil mycophenolate (MMF) or sirolimus as additional
second or third immunosuppressive agent in a few patients.
International guidelines concerning immunosuppression
were complied with in the case of new transplant patients,
but established immunosuppressive regimens were not routine-
ly altered in individual transplant patients. Corticosteroid
schedules included methylprednisolone at a dose of 500mg
given during the OLT procedure, followed by oral prednisolone
at a dose of 20mg daily for 1 week, 10mg daily for 3 months,
slowly tapering to complete discontinuation of corticosteroids
between 3 and 6 months after OLT in all but a few patients who
required maintenance doses of prednisolone of 2.5 to 10mg/d.
Treatment with calcium and vitamin D supplements in a
combined fixed dose of 500mg elemental calcium and 400 IU
cholecalciferol, and treatment with bisphosphonates were
initiated at the discretion of the treating physician. Patients
treated with bisphosphonates before or at the time of screening
for OLT were excluded from the study. Patients receiving
bisphosphonates after OLT were censored and thus excluded
from further analysis from time of starting treatment.
Methods
Demographic and clinical data
Patients’ demographic and clinical data were obtained from
electronic hospital records. Data on age, gender, smoking,
height, weight, and primary liver disease were collected.
Concomitant or later renal transplantation was documented.
Data were also collected on date and cause of death. Recorded
medication included immunosuppressives, calcium and vitamin
D supplements, and bone‐modifying medications such as
bisphosphonates.
Laboratory investigations
Laboratory data were also obtained from electronic hospital
records. Biochemical data collected included serum calcium,
corrected for an albumin of 40 g/L, phosphate, creatinine,
parathyroid hormone (PTH), and 25‐hydroxy‐vitamin D (25‐OHD)
concentrations, which were measured at screening for OLT and
at various time points thereafter. Severity of liver disease was
determined using the laboratory Model for End‐Stage Liver
Disease (MELD) scores(17) calculated on the basis of serum
creatinine, bilirubin, and international normalized ratio (INR)
measurements obtained at time of screening for OLT. The
following accepted formula was used to calculate the scores:
MELD ¼ 10 f½0:957 lnðCreatinine=88:4Þ
þ ½0:378 lnðBilirubin=17:1Þ
þ ½1:12 lnðINRÞ þ 6:43g
ð1Þ
BMD measurements
BMD was measured at the lumbar spine and at the femoral neck
using dual‐energy X‐ray absorptiometry (DXA Hologic QDR
4500; Hologic Inc., Waltham, MA, USA; equipped with reference
values based on the National Health and Nutrition Examination
Survey [NHANES III]). Absolutemeasurements of BMD in g/cm2 as
well as T‐scores (matched to young adult reference populations
at peak bonemass) and Z‐scores (age‐matched and sex‐matched
reference populations) were recorded. World Health Organiza-
tion (WHO) criteria were used to define osteoporosis (T‐score
of 2.5 SD or less) and osteopenia (T‐score between 1 SD
and 2.5 SD). BMD measurements were performed at time of
screening for OLT (baseline), at 6 and 12 months post‐OLT, and
yearly thereafter for up to 60 months after OLT. BMD measure-
ments at 36 and 48months post‐OLT were not analyzed because
too few measurements were available at these time points.
Vertebral fracture assessment
Spinal radiographs were routinely performed at time of
screening and at 6 and 12 months post‐OLT. Conventional
anteroposterior and lateral radiographs of the thoracic spine and
posteroanterior and lateral radiographs of the lumbar spine were
performed by an experienced radiology technician following a
standardized protocol, at a distance of 115 cm, with the film
centralized on Th7 for the thoracic spine and on L3 for the lumbar
spine.
All conventional radiographs of the thoracic and lumbar spine
were blindly assessed for the prevalence and individually scored
for the severity (grade) of vertebral fractures by two independent
observers, an experienced musculoskeletal radiologist (HMK)
and an experienced bone and mineral disorders specialist
(NATH). Vertebral fractures were assessed using the Genant’s
semiquantitative method.(18) Using this method, a decrease in
height of 20% to 25% is considered to be a “mild” grade I fracture,
25% to 40% a “moderate” grade II fracture, and>40% a “severe”
grade III fracture. Uniform loss of vertebral height compared to
adjacent vertebrae was additionally documented using the same
grading scores. Radiographs were assessed in a random order,
using random numbers generated by SPSS software, version 20
(SPSS Inc., Chicago, IL, USA). A unique number was assigned to
each series of radiographs. In case of discrepancy in scores,
consensus was achieved by both observers reviewing the
radiographs together.
Laboratory, BMD, and fracture data collected at time of
screening for OLT were considered to be baseline data.
The study was approved by the Medical Ethics Committee of
the Leiden University Medical Centre.
Statistical analysis
For descriptive statistics, categorical variables were expressed as
numbers and as percentages. Continuous variables were
summarized using mean and SD in case of normal distribution
of data; median and 5th and 95th percentiles were used
otherwise. An extension of a generalized linear model, general-
ized estimation equations (GEEs), was used for calculation of
differences in laboratory measurements and BMD, to account for
repeated measurements. Patients treated with bisphosphonates
were excluded from time of initiation of treatment for the
duration of follow‐up. Incidence rates for osteoporosis after OLT
(number of new cases/person years at risk) were calculated with
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follow‐up time starting after transplantation. Patients already
diagnosed as having osteoporosis at time of screening for OLT
were not included in the calculation of osteoporosis incidence.
An incident fracture was defined as the occurrence of a new
vertebral fracture or an increase in grade of a prevalent fracture
between serial radiographs before and during the first year after
OLT. Follow‐up duration until incident osteoporosis, or last
measurement of BMD, was used to calculate person‐years at risk.
A GEE model was used to evaluate the influence of various
factors on changes in BMD, corrected for age and gender, and
accounting for repeated measurements.
Prevalence of fractures was calculated by dividing the number
of patients with at least one vertebral fracture by the total
number of patients with available spinal radiographs. A GEE
model was used to evaluate the influence of change of BMD on
fracture risk, corrected for age and gender, and accounting for
repeated measurements. A univariate and multivariate logistic
regression model was used to evaluate risk factors for incident
fractures.
Calculations were performed using STATA/SE 12.0 software




Nine of the 223 eligible transplant recipients were not included in
the study because bone densitometry data were not available
after OLT and 13 patients were also not included because of
treatment with bisphosphonates before or at time of screening
for OLT.
Of the 201 patients included in the study, 142 weremen (71%).
Median age at time of OLT was 53 years (range, 18–70 years, with
only 4 patients being younger than 20 years). The most common
primary liver diseases were viral hepatitis (27%) and alcoholic
liver disease (25%), followed by cholestatic liver disease (14%)
(Table 1). At time of screening for OLT, 9 patients (5%) were using
corticosteroids, and calcium and vitamin D supplements were
prescribed as combination treatment to 21 patients (10%).
Laboratory data
Mean creatinine level was 92 67mmol/L (normal <104mmol/L).
Mean vitamin D level was 32 23 nmol/L (normal, 50–250 nmol/L),
125 patients (83%) had 25‐OH‐vitamin D levels<50 nmol/L, 87 of
whom had levels <30 nmol/L. Mean bilirubin level was 79
140mmol/L (normal <17mmol/L).
Severity of liver disease
Severity of liver disease at screening for OLT, as expressed by
laboratory‐MELD score, could be calculated in 196 of the 201
patients (98%). Mean score was 14 6 (range, 6–35).
BMD data
BMD measurements were available in 181 patients at time of
screening for OLT, but were technically non‐evaluable in 11
patients at the lumbar spine. Evaluation was precluded in these
11 patients by the presence of residual oral contrast material
from abdominal CT scans, required as part of the screening
protocol for OLT, but chronologically performed by error before
DXA. Osteoporosis and osteopenia were respectively found in
18% and 36% of patients at the lumbar spine (LS) and in 9 and
42% of patients at the femoral neck (FN).




Gender, male patients, n (%) 142 (71)
Age at time of OLT, years, median (range) 53 (18–70)
Death during follow‐up, n (%) 34 (17)
Time of death after OLT, months, median
(5th–95th percentile)
10 (1–57)
BMI, kg/m2, mean (SD) 26 (5)
Smoking, n (%) 64 (34)
Primary liver disease, n (%)
Viral 54 (27)
Alcoholic 51 (25)
Combined alcoholic and viral 4 (2)
Cholestatic (PSC/PBC/overlap syndrome) 29 (14)
Malignancy 12 (6)
Autoimmune hepatitis 10 (5)
Metabolic 7 (3)
Othera 34 (17)
Previous or concomitant renal
transplantation, n (%)
6 (3)




n (%) 28 (14)
Time to second OLT, days, median
(5th–95th percentile)
165 (2–1064)
Rejection episodes, number of episodes
(cumulative incidence, %)
6 months after OLT 27 (14)
12 months after OLT 30 (15)
24 months after OLT 42 (22)
60 months after OLT 42 (22)
Calcium and vitamin D supplements at
time of screening, n (%)
21 (10)
Bisphosphonates after OLT, n (%)
12 months 58 (32)
24 months 66 (43)
60 months 42 (48)
Corticosteroids at time of screening, n (%) 9 (5)
Immunosuppressive medication initiated
at OLT, n (%)
Prednisone, tacrolimus 88 (44)
Prednisone, cyclosporine 44 (22)
Prednisone, cyclosporine, and MMF 21 (10)
Prednisone, tacrolimus, and MMF 18 (9)
Other 30 (15
OLT¼orthotopic liver transplantation; BMI¼body mass index; PSC¼
primary sclerosing cholangitis; PBC¼primary biliary cirrhosis; MMF¼
mycophenolate mofetil.
aIncluding cryptogenic cirrhosis, Budd‐Chiari syndrome, portal vein
thrombosis, hereditary polycystic liver‐disease, acute liver failure of
pregnancy, medically induced cirrhosis, Caroli disease, cystic fibrosis, and
Rendu‐Osler‐Weber disease.
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Fracture data
A total of 176 patients had available conventional spinal
radiographs at time of screening for OLT. A total of 99 patients
(56%) had one or more vertebral fractures, mostly grade 1
fractures (87%). Of the patients with documented prevalent
vertebral fractures, 20 had osteoporosis (22%), 38 had osteopenia
(42%), and 41 had a normal BMD (36%).
Data after OLT
Clinical data
Median time between screening and OLT was 9 months (range,
0–66 months; 5th–95th percentile 1–27 months). All patients
received prednisone during the first 6 months after OLT.
Prednisone was combined with tacrolimus in 44% of patients
or with tacrolimus and MMF in 9% of patients. Cyclosporine was
given to 22% of patients and combined with MMF in 10% of
patients. Rejection episodes occurredmainly in the first 6months
after OLT (27 patients) with a cumulative incidence of 22% at
5 years after OLT. A second OLT was performed in 28 patients
(14%) after a median time of 7 months (range, 0–37 months).
Calcium and vitamin D supplements were increasingly pre-
scribed after OLT, with 26 patients (14%) receiving these
agents at screening, 107 (58%) at 1 year after OLT, and 68
patients (77%) at 5 years after OLT. Within the first year after OLT,
bisphosphonate treatment was initiated in 58 patients (32%),
and 42 patients (48%) were using these agents at 5 years after
OLT.Median timeof initiation of bisphosphonateswas 12months
after OLT (range, 12–48 months).
Six patients (3%) received a previous or concomitant renal
transplantation. Thirty‐four patients (17%) died during the
follow‐up period, at a median time of 10 months after OLT
(range, 1–58 months). The most common cause of death was
infection (n¼ 7) and recurrence of hepatocellular carcinoma
(n¼ 5). Other causes included myocardial infarction, hypoglyce-
mia, and suicide.
Laboratory data
There was a significant improvement in liver function tests with
time after OLT, with mean bilirubin level decreasing from
78 141mmol/L at screening to 20 35mmol/L (p< 0.005) at
12 months and to 20 60mmol/L at 2 years after OLT
(p< 0.005), stabilizing thereafter with bilirubin levels of 15 13
mmol/L at 5 years after OLT. There was a mild but significant
decrease in renal function after OLT, with mean creatinine level
increasing from 92 67mmol/L at time of screening for OLT to
113 50mmol/L at 12 months after OLT (p< 0.005), stabilizing
thereafter with a mean creatinine level of 111 66mmol/L at
5 years after OLT. Mean vitamin D levels increased from 32 23
nmol/L at time of screening to 51 28 nmol/L at 12months after
OLT (p< 0.005) and to 60 29 nmol/L at 5 years after OLT
(p< 0.005).
Changes in BMD after OLT
Sequential changes in BMD were analyzed in the 201 patients
included in the study. BMD measurements were not available at
screening in 20 of these patients but sequential data were
available from 6 months onward after OLT. BMD declined
significantly at both LS and FN sites between screening and
6 months after OLT: LS 0.02 g/cm2 (2.5%), p¼ 0.002; FN
0.05 g/cm2 (6.5%), p< 0.005), stabilizing thereafter until
12 months after OLT (Fig. 1). Between 1 and 2 years after OLT,
LS T‐scores increased by 1.2% (0.02 g/cm2, p¼ 0.012), reaching
pretransplantation values at 2 years after OLT and subsequently
remaining stable. In contrast, FN BMD remained consistently
below pretransplantation values, but after the initial significant
loss demonstrated no further decline up to 5 years of follow‐up
(Fig. 1). A second OLT did not influence the course of changes in
BMD. Incidence rates of osteoporosis at the LS and FN were 4.2
and 4.7 per 100 person‐years after OLT, respectively. The
cumulative incidence of osteoporosis at the LS was 7% at
6 months, 12.1% at 12 months, and 14.7% at 5 years (Fig. 2). The
cumulative incidence of osteoporosis at the FN was 8.5%
at 6 months, 10.5% at 12 months, and 19.5% at 5 years after OLT.
Incidence of fractures after OLT
Spinal radiographs were available and evaluable in 115 patients
at 6months after OLT and in 106 patients at 12months after OLT.
Fig. 1. Changes in LS and FN T‐scores in patients not treated with bone‐
modifying agents after OLT. #Significant decrease p< 0.05 compared to
values at the time of screening. Significant increase p< 0.05 when
compared to values at 12 months after OLT. LS¼ lumbar spine;
FN¼ femoral neck; OLT¼ orthotopic liver transplantation.
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The prevalence of fractures increased from 56% at time of
screening to 78 of 115 patients (68%) at 6 months after OLT, and
to 75 of 106 patients (71%) at 12 months after OLT. Incident
fractures occurred in 45 of 133 patients (34%) in whom a second
spinal radiograph was available during the first year after
transplantation.
Risk factors for bone loss and for vertebral fractures after
OLT
We studied the effect of age, gender, primary liver disease,
severity of liver disease, BMD at screening for OLT, and
immunosuppressive regimens, including corticosteroids, on
bone loss and fracture risk within the first year after OLT. Of
these potential risk factors thatmay influence BMD, the only ones
with a significant relationship with bone loss were age52 years
in women (pragmatic cutoff age for menopause) (odds ratio [OR]
0.89; 95% confidence interval [CI], 0.81–0.99; p¼ 0.0024), and the
use of the calcineurin inhibitor tacrolimus for immunosuppres-
sion (OR 0.95; 95% CI, 0.91–0.98; p¼ 0.003). Vitamin D deficiency
was not predictive for bone loss either at the LS (OR 0.95; 95% CI,
0.90–1.01; p¼ 0.080) or at the FN (OR 0.99; 95% CI, 0.95–1.04;
p¼ 0.674). Patients with alcoholic liver disease demonstrated an
increase, rather than a decrease, in LS BMD but not FN BMD after
OLT (at LS: OR 1.08; 95% CI, 1.02–1.14; p¼ 0.005; at FN: OR 1.03;
95% CI, 0.99–1.08; p¼ 0.187).
Of the potential risk factors studied, onlymale gender (OR 5.15;
95% CI, 1.41–18.8; p¼ 0.013), and higher age (OR 1.06; 95% CI,
1.00–1.11; p¼ 0.045) were associated with an increased risk for
incident fractures. Other factors, including cholestatic liver
disease, severity of liver disease, LS BMD, and prevalent fractures
at time of screening for OLT, were not predictive for increased
fracture risk after OLT. There was no relationship between
immunosuppressive medication and fracture risk. There was no
difference in pattern of change in BMD at the LS or FN in patients
with incident vertebral fractures within the first year after OLT
compared to those who did not sustain a fracture (LS BMD: OR
0.97; 95% CI, 0.91–1.03; p¼ 0.293; FN BMD: OR 0.97; 95% CI, 0.93–
1.02; p¼ 0.272).
Discussion
Our findings from this study of longitudinal changes in BMD
and vertebral fracture incidence in a cohort of recipients of an
OLT show a high prevalence of osteopenia/osteoporosis and
vertebral fractures at time of screening for OLT. Of patients with
diverse primary liver pathology, 54% had some degree of bone
loss and 56% had prevalent vertebral fractures. Despite the high
prevalence of skeletal pathology in these patients with end‐stage
liver disease awaiting liver transplantation, only a few received
treatment with a bisphosphonate, which provided us the unique
opportunity of studying sequential changes in BMD and fracture
risk in a relatively large number of OLT recipients not receiving
bone‐modifying treatment. In keepingwith previously published
studies, with up to 2 years follow‐up after OLT,(1–3,7,9,10,12,13,16) we
observed significant bone loss at both the LS and FN sites
between screening and 6 months after OLT. Spontaneous
recovery of BMD to pretransplantation values was observed at
the LS within 2 years after OLT, with our longer‐term data
showing stabilization of LS BMD thereafter for up to 5 years after
OLT. In contrast to the increase in BMD observed at the LS after
the initial rapid post‐OLT decline in BMD, there was no similar
recovery of BMD at the FN. Data on long‐term changes in FN
BMD after OLT are scarce and not always concordant.(1,5,9,13)
Whereas some studies show an increase in FN BMD during the
second year after OLT,(1,5) other studies show a persistently low
FN BMD compared to pretransplantation values, or a further
decline in bone mass at cortical sites.(6,9,13,15,16) The discrepancy
in behavior of BMD between LS and FN sites is likely to be a result
of the difference in proportion of trabecular and cortical bone
between these two sites. Trabecular bone comprises 66% of total
bone at the vertebrae, whereas cortical bone comprises>75% of
the total bone composition of the FN. Trabecular bone is much
more susceptible to changes in the bone microenvironment
resulting from disease processes than cortical bone, just as it is
more readily susceptible to pharmacologic interventions. BMD at
the LS thus shows the greatest magnitude and speed of change
in response to reversal of diseases processes as well as to
pharmacological interventions, such as has been repeatedly
demonstrated with the use of antiresorptives or anabolic agents
in the management of osteoporosis. After successful OLT,
reversal of cholestasis, vitamin D deficiency, and hypogonadism,
which follows the restoration of liver function, is likely to
significantly contribute to the spontaneous improvement in LS
BMD, with recovery of FN BMD lagging behind that of LS BMD up
to 5 years after OLT.
Fig. 2. Kaplan‐Meier survival curve showing incident osteoporosis at the
LS (upper panel) and FN (lower panel) after OLT. LS¼ lumbar spine,
FN¼ femoral neck, OLT¼ orthotopic liver transplantation.
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Corticosteroids form the mainstay of the induction and
maintenance of immunosuppression after solid organ transplan-
tation, and these agents are used in nearly all immunosuppres-
sive protocols. An association between corticosteroid use and
early posttransplantation bone loss has been observed in the
early stages of solid organ transplantation.(8) However, the
introduction of new immunosuppressive regimens has allowed
the early tapering of corticosteroids, thereby substantially
contributing to long‐term recovery of bone mass after
transplantation. Nonetheless, acute rejection episodes occur
more commonly in the first 3 months after transplantation, so
that corticosteroid withdrawal is only practical thereafter.
In our study, only few of the risk factors evaluated at screening
for OLT, which may potentially influence BMD, were able to
predict bone loss or its severity post‐OLT. Alcoholic liver disease
was, interestingly, but perhaps not surprisingly, associated with
no decrease in BMD after OLT. Alcohol is toxic to the osteoblast
and alcohol abuse is associatedwith a low turnover osteoporosis.
Alcohol withdrawal is a prerequisite for liver transplantation, and
candidates for OLT have to be completely dry for at least
6 months before being eligible for transplantation. In transplant
recipients with alcoholic liver disease, removal of the toxic effect
of alcohol on the osteoblast before transplantation, in addition to
the improvement in nutritional status, when alcohol does no
longer represent the major source of caloric intake, could well
explain the lack of deterioration of bone mass after OLT in
patients with this liver pathology.
We found no relationship between graft function, corticoster-
oid use, number of graft rejection episodes, or persistent vitamin
D deficiency on the degree of bone loss after OLT. This is also in
keeping with data from a number of studies addressing the role
of these factors on post‐OLT bone loss,(1,3,4,8,9,12–14) although
some other studies did find an association between cholestatic
liver disease, cumulative prednisone dose, and bone loss after
OLT.(5,6,8)
Previously published data on fracture incidence after OLT
show wide variability, ranging from 10% to 33% within the first
year after OLT.(5,7,9,11,14,15,19) Our data on 1‐year fracture
incidence are in keeping with only one previously published
study, in which a semiquantitative method of evaluation of
vertebral fractures on routinely performed conventional spinal
radiographs was also used, and the evaluation was performed by
two independent observers on sequential radiographs.(9)
Another reason for the discrepancy in fracture incidence
between our study and that of others may be that previous
studies were performed with smaller numbers of pa-
tients,(5,9,14,15,20) or in patients with only cholestatic liver disease
as primary liver pathology.(19) Furthermore, although conven-
tional spine radiographs were performed in some studies, these
were not evaluated by semiquantitative methods, which may
have also led to underestimation of fracture incidence since
routine radiology reports tend to underreport specially mild
grade fractures.
Data on risk factors for incident fractures after OLT are
conflicting. BMD measurements have been found to be
predictive in some studies,(9,14,15,19) but not in others.(7,11) In
our study, both BMD at time of screening as well as changes of
BMD within the first year after OLT were not predictive for
fracture risk. Whereas some studies showed prevalent fractures
before OLT to be associated with increased fracture risk after
transplantation,(11,19,20) this was not the case in our study. These
data suggest that the absence of low bonemass and of prevalent
fractures before OLT does not preclude an increased risk for
fracture after transplantation so that it is of significant clinical
relevance that liver transplant recipients should be regularly
screened for the presence of these fractures and treated
accordingly.
Our study has a number of strengths as well as limitations. Its
main strength lies in the relatively large representative cohort of
patients studied, the availability of sequential BMD measure-
ments as only inclusion criterion, providing a minimal selection
bias, and the opportunity to study changes in BMD for a relatively
long period after OLT without the confounding influence of
bone‐modifying treatment on BMD. Another strength of our
study is the availability of serial spinal radiographs within the first
year after transplantation in a large number of patients, and the
blinded semiquantitative assessment of all spinal radiographs for
vertebral fractures by two experienced independent observers.
Our study has also a number of limitations. There were no
predefined treatment protocols for immunosuppressive regi-
mens, or for indication for bisphosphonate therapy. These
patient management decisions were left to the clinical judgment
of the treating physician andmay have provided some degree of
bias. Another limitation may be our choice to exclude patients
from the time of initiation of bisphosphonate treatment, using
“last observation carried forward” to minimize the effect of this
censoring on our data. Because patients excluded from further
analysis owing to starting therapy were most likely to have
continuing bone loss if left untreated, the increase in BMD
reported in the remaining untreated patients may have been
overestimated, although the number of patients treated is
smaller than the number of untreated patients. Because
treatment with different immunosuppressive regimens was
not randomly assigned, the effect of these regimens on patterns
of bone loss after OLT could also not be compared. A further
limitation of our study is the variable time lag between screening
for OLT and date of transplantation. Because the median time
between screening and OLT was 9 months, it is conceivable that
further bone loss and new fractures may have occurred between
screening and transplantation, with possible further decrease in
liver function and worsening cholestasis potentially contributing
to worsening of skeletal pathology. However, this limitation is
common to most published studies, with the majority failing to
report time lag between pretransplantation and posttransplan-
tation measurements.(1–5,7,12–14) Although the heterogeneity of
the population studied may be perceived as a limitation, we did
not consider this to be the case, because the distribution of
primary liver pathology was fairly representative of OLT
populations, patients receiving bisphosphonates were excluded
from the analysis, and patients receiving a second liver transplant
did not have a different course of changes of BMD. Only 12
patients (6%) were using corticosteroids at screening and use of
these agents posttransplantation would override the effect of
the pretransplantation use of these agents.
In conclusion, osteopenia, osteoporosis, and vertebral frac-
tures are prevalent in prospective liver transplant recipients. An
overall decline in BMD is observed within the first 6 months after
OLT, with subsequent spontaneous recovery to pretransplanta-
tion values at the LS, but not at the FN, up to 5 years after OLT.
The incidence of vertebral fractures is high within the first year
after OLT with poor association between pretransplantation
factors, changes of BMD, and fracture risk. Although our findings
highlight the spontaneous recovery of BMD associated with
restoration of liver function, and its maintenance in the long term
after liver transplantation, our data also demonstrate that the
spontaneous recovery in BMD was not associated with a
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corresponding decrease in fracture risk, at least within the first
year after OLT, suggesting a potentially persistent or irreversible
effect of liver disease on bone quality and fracture risk. Whether
treatment with bisphosphonates or other bone‐modifying
agents may be able to decrease or prevent fracture risk within
the first year after liver transplantation and in the longer term
thereafter remains to be established.
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